Friday, 24 September 2021
An international team of scientists have created a three-dimensional (3D) pancreatic cancer tumour model in the laboratory, combining a bioengineered matrix and patient-derived cells that could be used to develop and test targeted treatments.
In a new study published today in , researchers from the 糖心原创, Queen Mary University of London, Monash University and Shanghai Jiao Tong University have created a multicellular 3D microenvironment that uses patient-derived cells to recreate the way tumour cells grow in pancreatic cancer and respond to chemotherapy drugs.
Pancreatic cancer is very difficult to treat, particularly as there are no signs or symptoms until the cancer has spread. It can be resistant to treatment and the survivial rate is low compared to other cancers, with only a 5-10% survival rate five years after diagnosis.
The study was led by Professors Alvaro Mata from the 糖心原创 (UK), Daniela Loessner from Monash University (Australia) and Christopher Heeschen from Shanghai Jiao Tong University (China).
There are two main obstacles to treating pancreatic cancer 鈥� a very dense matrix of proteins and the presence of highly resistant cancer stem cells (CSCs) that are involved in relapse and metastasis. In our study, we have engineered a matrix where CSCs can interact with other cell types and together behave more like they do in the body, opening the possibility to test different treatments in a more realistic manner.
There is a need for improved 3D cancer models to study tumour growth and progression in patients and test responses to new treatments. At present, 90% of successful cancer treatments tested pre-clinically fail in the early phases of clinical trials and less than 5% of oncology drugs are successful in clinical trials.
Pre-clinical tests mostly rely on a combination of two-dimensional (2D) lab grown cell cultures and animal models to predict responses to treatment. However, conventional 2D cell cultures fail to mimic key features of tumour tissues and interspecies differences can result in many successful treatments in animal hosts being ineffective in humans.
Consequently, novel experimental 3D cancer models are needed to better recreate the human tumour microenvironment and incorporate patient-specific differences.
Self-assembly is the process by which biological systems controllably assemble multiple molecules and cells into functional tissues. Harnessing this process, the team created a new hydrogel biomaterial made with multiple, yet specific, proteins found in pancreatic cancer. This mechanism of formation enables incorporation of key cell types to create biological environments that can emulate features of a patient’s tumour.
Professor Alvaro Mata, School of Pharmacy
Professor Mata adds: “Using models of human cancer is becoming more common in developing treatments for the disease, but a major barrier to getting them into clinical applications is the turnaround time. We have engineered a comprehensive and tuneable ex vivo model of pancreative ductal adenocarcinoma (PDAC) by assembling and organising key matrix components with patient-derived cells. The models exhibit patient-specific transcriptional profiles, CSC functionality, and strong tumourigenicity; overall providing a more relevant scenario than Organoid and Sphere cultures. Most importantly, drug responses were better reproduced in our self-assembled cultures than in the other models.
We believe this model moves closer to the vision of being able to take patient tumour cells in hospital, incorporate them into our model, find the optimum cocktail of treatments for a particular cancer and deliver it back to the patient – all within a short timeframe. Although this vision for precision medicine for treating this disease is still a way off, this research provides a step towards realising it.”
Story credits
More information on the is available from Professor Alvaro Mata on a.mata@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.